LPGAT1

Across TCGA pan-cancer cohorts, LPGAT1 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated LPGAT1 data layer compared with 23 for mass-spec protein and 2 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher LPGAT1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated LPGAT1 expression acts as an unfavorable survival marker.

LSCC, LUAD, and COAD are the cancer types where LPGAT1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Quartile	All	0.565	0.920	.002	26	view →
LUAD	OS	Quartile	All	0.743	0.955	.004	17	view →
COAD	DFS	Median	IV	0.565	1.000	.028	12	view →
PDAC	DFS	Quartile	All	0.345	0.497	.049	2	view →
CCRCC	OS	Tertile	All	0.659	1.000	.024	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

LPGAT1–LSCC (DFS)

Open the LSCC breakdown →